• Clinical Trials - Pancreatic cancer

    Study Objective Contact
    A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined with nab-Paclitaxel Plus Gemcitabine Compared with nab-Paclitaxel Plus Gemcitabine in Subjects with Stage IV Previously Untreated Pancreatic Cancer [LCID Study Number: 2013-035] This protocol compares the effects of standard of care treatment (nab-paclitaxel and gemcitabine) to the standard of care plus PEGPH20 in patients with stage IV pancreatic cancer. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Francis W. Nugent, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Erin H. Hartnett.
    A Phase III Study Of Chemotherapy And Chemoradiotherapy With Or Without HyperAcute®-Pancreas (algenpantucel-L)Immunotherapy in Subjects With Surgically Resected Pancreatic Cancer [LCID Study Number: 2010-059] The purpose of this study is to determine the efficacy of giving subjects with pancreatic cancer the HyperAcute® Pancreas immunotherapy (experimental) along with chemotherapy and chemoradiation (standard). The study immunotherapy is made of two (2) genetically engineered human pancreatic cancer cell types. The purpose of this study is to compare the effects, good and/or bad, of standard of care therapy (gemcitabine alone or with chemoradiation) with or without the addition of HyperAcute®-Pancreas immunotherapy to find out which treatment is better. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Francis W. Nugent, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Deborah J. Gannon.
    Compassionate Use of HyperAcute-Pancreas (algenpantucel-L) Immunotherapy in Subject with Surgically Resected Pancreatic Cancer [LCID Study Number: 2013-018] The purpose of this study is to give patients diagnosed with pancreatic cancer the opportunity to receive standard of care therapy (gemcitabine) with the addition of HyperAcute®-Pancreas immunotherapy. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Francis W. Nugent, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Deborah J. Gannon.
    E2211: A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors [LCID Study Number: 2013-040] This protocol addresses whether the combination of temozolomide and capecitabine works better than temozolamide alone on advanced pancreatic neuroendocrine tumor cancer. Principal Investigator(s):
    Keith E. Stuart, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Charles A. Stagno-Scotto,
    Erin H. Hartnett.
    Molecular Analysis of Cancer [LCID Study Number: 2011-048] The purpose of this research is to discover molecular changes involved in cancer. We hope that a better understanding of these changes can improve cancer management. This research may include genetic and/or genomic analysis (tests to determine and compare your genetic sequence, or DNA). Some of the tissue we collect for our research may be submitted to the National Cancer Institute Cancer Genome Atlas Project. The goal of this project is to determine the genomic changes involved in more than 20 types of human cancer. Principal Investigator(s):
    Kimberly R. Christ, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Doreen L. Browne, ,CCRP,
    Jane S. Nalwalk,
    Linda M. Topjian.
    Phase I/II Study Of RAD001 In Combination With Temozolomide In Patients With Advanced Pancreatic Neuroendocrine Tumors [LCID Study Number: 2008-036] The purpose of this research is to test the safety and efficacy of an investigational drug, RAD001, in combination with temozolomide in patients with pancreatic neuroendocrine tumors. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Keith E. Stuart, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Sherry G. Heldt, RN.
    RTOG 0848: A Phase II-R and A Phase III Trial Evaluating Both *Erlotinib (PH II-R)and Chemoradiation (PH III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma [LCID Study Number: 2014-018] To determine whether the use of 5-FU with radiation following post-surgery chemotherapy further enhances survival for such patients who do not show disease progression after 5 cycles of chemotherapy. Principal Investigator(s):
    Keith E. Stuart, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Amanda M. Pietras,
    Charles A. Stagno-Scotto.